Transdermal system of tacrine/selegilin-plaster
    21.
    发明授权
    Transdermal system of tacrine/selegilin-plaster 失效
    他克林/塞莱格林膏药的透皮系统

    公开(公告)号:US5972376A

    公开(公告)日:1999-10-26

    申请号:US43231

    申请日:1998-03-12

    IPC分类号: A61K9/70 A61F13/00

    摘要: The invention relates to a plaster for transdermal application with an outer covering or backing layer, a self-adhesive matrix or a reservoir and a removable protective liner or release layer, the matrix or the reservoir containing tacrine and selegiline (optionally in the form of their pharmaceutically compatible salts) as active substance.

    摘要翻译: PCT No.PCT / EP96 / 04010 Sec。 371日期1998年3月12日 102(e)1998年3月12日PCT PCT 1996年9月12日PCT公布。 公开号WO97 / 09969 日期1997年3月20日本发明涉及一种用于透皮施用的石膏,其具有外覆盖物或背衬层,自粘基质或储存器和可移除的保护性衬垫或释放层,所述基质或储存器含有他克林和司来吉兰(任选地 以其药学上相容的盐的形式)作为活性物质。

    Crystalline cyclodextrin complexes of ranitidine hydrochloride, process
for their preparation and pharmaceutical compositions containing the
same
    22.
    发明授权
    Crystalline cyclodextrin complexes of ranitidine hydrochloride, process for their preparation and pharmaceutical compositions containing the same 失效
    雷尼替丁盐酸盐的结晶环糊精复合物,其制备方法和含有它们的药物组合物

    公开(公告)号:US5665767A

    公开(公告)日:1997-09-09

    申请号:US513779

    申请日:1995-12-15

    摘要: The present invention relates to cyclodextrin inclusion complexes of ranitidine hydrochloride which exhibit a novel, to date unknown crystalline structure, being significantly different from those of known "Form 1 and 2" and to the preparation of such inclusion complexes. The inclusion complexes are prepared from aqueous common solution or suspensions of ranitidine hydrochloride and cyclodextrin by removal of water. As complexing agents .alpha.-, .beta.- and gamma-cyclodextrins, their alkylated, hydroxy alkylated derivates or their suitable mixtures are utilized. Finally, the invention concerns pharmaceutical compositions comprising the new complexes.

    摘要翻译: PCT No.PCT / EP94 / 00645 Sec。 371 1995年12月15日第 102(e)日期1995年12月15日PCT 1994年3月4日PCT公布。 WO94 / 20091 PCT出版物 日期1994年9月15日本发明涉及盐酸雷尼替丁的环糊精包合配合物,其显示出迄今为止未知的结晶结构,与已知的“形式1和2”显着不同,并且制备这种包合物。 通过除去水,从盐酸雷尼替丁和环糊精的普通溶液或悬浮液中制备包合物。 作为络合剂α - ,β-和γ-环糊精,使用它们的烷基化羟基烷基化衍生物或其合适的混合物。 最后,本发明涉及包含新配合物的药物组合物。

    Shunt element
    23.
    发明授权
    Shunt element 失效
    分流元件

    公开(公告)号:US4414297A

    公开(公告)日:1983-11-08

    申请号:US371121

    申请日:1982-04-23

    申请人: Wilfried Fischer

    发明人: Wilfried Fischer

    摘要: Shunt element for an electrochemical storage cell or a group of several parallel-connected storage cells of the alkali metal and chalcogen type, with at least one anode space for the anolyte and a cathode space for the catholyte, which spaces are separated from each other by an alkali ion-conducting solid electrolyte wall and, at least in places, are bounded by a metallic housing. The shunt element has at least two directly adjoining spaces which can be connected to each other. The first such space is filled with a metal or with a decomposable metal compound. The second such space contains the contact surfaces of at least two electrodes which are arranged at a defined distance from each other. The first electrode is additionally connected to at least one electron-conducting surface of the first space. The two electrodes can be connected to the storage cell or cells.

    摘要翻译: 用于电化学存储电池或一组几个并联连接的碱金属和硫属类型存储电池的分流元件,具有至少一个用于阳极电解液的阳极空间和用于阴极电解液的阴极空间,这些空间通过 碱性离子导电固体电解质壁,并且至少在某些地方由金属壳体限定。 分路元件具有至少两个可相互连接的直接邻接的空间。 第一个这样的空间用金属或可分解的金属化合物填充。 第二个这样的空间包含至少两个电极的接触表面,这两个电极被设置成彼此限定的距离。 第一电极另外连接到第一空间的至少一个电子传导表面。 两个电极可以连接到存储单元或单元。

    Device for administering liquids
    25.
    发明授权
    Device for administering liquids 失效
    用于给药液体的装置

    公开(公告)号:US06948636B1

    公开(公告)日:2005-09-27

    申请号:US10415571

    申请日:2000-10-31

    IPC分类号: A61M5/145 A61M5/148 B65D35/28

    CPC分类号: A61M5/148 A61M2005/14506

    摘要: A device for dispensing liquid from a bag has upper and lower casing halves and a closure holding together the casing halves. A pressure piston in the casing can press the bag against the lower casing half. This piston is operated by a rocking lever having an upper end bearing on the upper casing half and a lower end on which the piston is pivoted and a tension spring and flexible element connected between the casing halves and the upper end of the rocking lever and angularly biasing the lever for movement from a generally horizontal position with the piston raised and a tilted position with the piston lowered for applying such a force to the pressure piston that a pressure is generated in the bag that causes the discharge of a constant liquid volume per unit of time.

    摘要翻译: 用于从袋分配液体的装置具有上半壳体和下壳体半部以及将壳体半部保持在一起的封闭件。 壳体中的压力活塞可以将袋子压靠在下半壳体上。 该活塞由在上壳体半体上具有上端轴承和活塞枢转的下端的摇臂操作,并且拉伸弹簧和柔性元件连接在壳体半部和摇臂的上端之间,并且具有角度 偏压杠杆从大体上水平的位置移动,活塞升高,并且活塞倾斜的位置降低,以向压力活塞施加这样的力,从而在袋中产生压力,从而使每单位排出恒定的液体体积 的时间。

    Controlled-release pharmaceutical preparation comprising an ACE inhibitor as active ingredient
    28.
    发明授权
    Controlled-release pharmaceutical preparation comprising an ACE inhibitor as active ingredient 失效
    包含ACE抑制剂作为有效成分的控释药物制剂

    公开(公告)号:US06267990B1

    公开(公告)日:2001-07-31

    申请号:US09460055

    申请日:1999-12-13

    IPC分类号: A61K916

    CPC分类号: A61K9/5084 A61K31/401

    摘要: The invention relates to a pharmaceutical preparation which comprises or consists of the following components: (i) an initial dose of active ingredient, which is provided by the active ingredient together with optional excipients, (ii) a first delayed-release type of pellet, in which the active ingredient and optional excipients are covered with a coating, and (iii) a second delayed-release type of pellet, in which the active ingredient and optional excipients are again covered with a coating, wherein the active ingredient is an ACE inhibitor, and wherein the amounts of the coatings according to (ii) and (iii) are present in a ratio, based on weight, within the range of from 1:2 to 1:7.

    摘要翻译: 本发明涉及一种药物制剂,其包含或由以下组分组成:(i)活性成分的初始剂量,其由活性成分与任选的赋形剂一起提供,(ii)第一延迟释放型颗粒, 其中活性成分和任选的赋形剂用涂层覆盖,和(iii)第二延迟释放型颗粒,其中活性成分和任选的赋形剂再次用涂层覆盖,其中活性成分是ACE抑制剂 ,并且其中根据(ii)和(iii)的涂料的量以基于重量在1:2至1:7的范围内的比例存在。

    Tablet or capsule having a content of stable ranitidine hydrochloride
form 1
    30.
    发明授权
    Tablet or capsule having a content of stable ranitidine hydrochloride form 1 失效
    具有稳定的盐酸雷尼替丁形式的片剂或胶囊形式1

    公开(公告)号:US5910320A

    公开(公告)日:1999-06-08

    申请号:US652439

    申请日:1996-08-19

    IPC分类号: A61K9/20 A61K31/34

    摘要: The invention relates to a tablet or capsule that is characterised by a powder mixture having a content of stable ranitidine hydrochloride Form 1 together with a carrier and/or diluent, and to manufacturing processes for the tablet.

    摘要翻译: PCT No.PCT / EP94 / 04044 Sec。 371日期:1996年8月19日 102(e)日期1996年8月19日PCT 1994年12月5日PCT公布。 出版物WO95 / 15162 日期1995年6月8日本发明涉及一种片剂或胶囊,其特征在于具有稳定的盐酸雷尼替丁形式1的含量与载体和/或稀释剂一起的粉末混合物,以及片剂的制造方法。